Aeras partners with Crucell to develop TB vaccine
The Crucell-Aeras TB vaccine program will focus on improvement of the only currently available TB vaccine, Bacillus Calmette-Guérin (BCG), using Crucell's proprietary PER.C6ä and AdVacä technologies. With this collaboration contract, Crucell's early stage TB vaccine development is fully funded up to entering the clinic.
"Currently one-third of the world's population is infected with TB, and someone is newly infected every second. A new vaccine is the best hope for defeating this terrible disease," said Dr. Jerald Sadoff, President & Chief Executive Officer of the Aeras Global TB Vaccine Foundation. "We chose Crucell to develop a candidate TB vaccine because the company's vector technology is among the best in the world."
Crucell's tuberculosis and malaria vaccine candidates are both based on the Company's PER.C6(TM) and AdVac(TM) technologies. "We see this collaboration with Aeras as a strong endorsement of Crucell's vaccine programs" stated Ronald Brus, Chief Executive Officer of Crucell. "Crucell aims to improve the existing vaccine against TB, a disease which kills over two million people globally per year." Jaap Goudsmit, Chief Scientific Officer at Crucell, added, "Our AdVac(TM) technology is designed to deliver the protection against TB required at the scale needed to have impact on this devastating TB epidemic. We think we can contribute with our technology to the improvement of global health."
Dr. Sadoff added, "We are very pleased to be working with Crucell and to be able to use their advanced technology to develop new TB vaccines, which the world so desperately needs." The Bill & Melinda Gates Foundation recently awarded Aeras a grant of USD$82.9 million for new TB vaccine development. Aeras aims to work with leading public and private organizations around the world to bring an improved TB vaccine to market within the next 7 to 10 years.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.